Want to see IMVT full AI Analyst Report?

Immunovant (IMVT) Stock Forecast & Price Target

961 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMVT Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Immunovant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMVT Stock 12 Month Forecast

Average Price Target

$50.55

▲(28.26% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $50.55 with a high forecast of $66.00 and a low forecast of $30.00. The average price target represents a 28.26% change from the last price of $39.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","67":"$67","27.25":"$27.3","40.5":"$40.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.54545454545454,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,27.25,40.5,53.75,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.62,40.72615384615384,42.832307692307694,44.93846153846154,47.04461538461538,49.15076923076923,51.25692307692307,53.363076923076925,55.46923076923077,57.575384615384614,59.681538461538466,61.78769230769231,63.893846153846155,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.62,39.537342657342656,40.454685314685314,41.372027972027965,42.28937062937062,43.20671328671328,44.12405594405594,45.0413986013986,45.958741258741256,46.876083916083914,47.79342657342657,48.71076923076922,49.62811188811188,{"y":50.54545454545454,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.62,37.956923076923076,37.293846153846154,36.63076923076923,35.9676923076923,35.30461538461538,34.64153846153846,33.97846153846154,33.315384615384616,32.652307692307694,31.98923076923077,31.326153846153844,30.663076923076922,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.86,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$66.00

Average Price Target$50.55

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$40→$41

Buy

4.03%

Upside

Reiterated

08/10/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)

Brian Cheng

J.P. Morgan

$50

Buy

26.87%

Upside

Reiterated

08/10/26

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

Sam Slutsky

LifeSci Capital

$53

Buy

34.48%

Upside

Reiterated

08/07/26

Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained

Yasmeen Rahimi

Piper Sandler

$66

Buy

67.47%

Upside

Reiterated

08/07/26

Piper Sandler Reaffirms Their Buy Rating on Immunovant (IMVT)

Danielle Brill

Truist Financial

$30

Hold

-23.88%

Downside

Reiterated

08/07/26

Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

37.02%

Upside

Reiterated

08/07/26

Immunovant (IMVT) Receives a Buy from Oppenheimer

Dina Ramadane

Bank of America Securities

$43→$45

Buy

14.18%

Upside

Reiterated

08/07/26

Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)

Samantha Semenkow

Citi

$57→$61

Buy

54.78%

Upside

Reiterated

06/30/26

Immunovant price target raised to $61 from $57 at CitiImmunovant price target raised to $61 from $57 at Citi

Yatin Suneja

Guggenheim

$44→$62

Buy

57.32%

Upside

Reiterated

05/26/26

Analysts' Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)

Alex Thompson CFA

Stifel Nicolaus

$49

Buy

24.33%

Upside

Reiterated

05/25/26

Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Erasca (NASDAQ: ERAS)

Derek Archila

Wells Fargo

$45

Buy

14.18%

Upside

Reiterated

05/21/26

Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)

Corinne Johnson

Goldman Sachs

$29→$32

Hold

-18.80%

Downside

Assigned

04/15/26

Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs

Andy Chen

Wolfe Research

$47

Buy

19.26%

Upside

Reiterated

04/06/26

Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential

Thomas Smith

Leerink Partners

$52→$50

Buy

26.87%

Upside

Reiterated

04/02/26

Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback

William Pickering

Bernstein

$28

Hold

-28.95%

Downside

Initiated

03/20/26

Immunovant initiated with a Market Perform at BernsteinImmunovant initiated with a Market Perform at Bernstein

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$40→$41

Buy

4.03%

Upside

Reiterated

08/10/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)

Brian Cheng

J.P. Morgan

$50

Buy

26.87%

Upside

Reiterated

08/10/26

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

Sam Slutsky

LifeSci Capital

$53

Buy

34.48%

Upside

Reiterated

08/07/26

Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained

Yasmeen Rahimi

Piper Sandler

$66

Buy

67.47%

Upside

Reiterated

08/07/26

Piper Sandler Reaffirms Their Buy Rating on Immunovant (IMVT)

Danielle Brill

Truist Financial

$30

Hold

-23.88%

Downside

Reiterated

08/07/26

Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

37.02%

Upside

Reiterated

08/07/26

Immunovant (IMVT) Receives a Buy from Oppenheimer

Dina Ramadane

Bank of America Securities

$43→$45

Buy

14.18%

Upside

Reiterated

08/07/26

Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)

Samantha Semenkow

Citi

$57→$61

Buy

54.78%

Upside

Reiterated

06/30/26

Immunovant price target raised to $61 from $57 at CitiImmunovant price target raised to $61 from $57 at Citi

Yatin Suneja

Guggenheim

$44→$62

Buy

57.32%

Upside

Reiterated

05/26/26

Analysts' Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)

Alex Thompson CFA

Stifel Nicolaus

$49

Buy

24.33%

Upside

Reiterated

05/25/26

Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Erasca (NASDAQ: ERAS)

Derek Archila

Wells Fargo

$45

Buy

14.18%

Upside

Reiterated

05/21/26

Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)

Corinne Johnson

Goldman Sachs

$29→$32

Hold

-18.80%

Downside

Assigned

04/15/26

Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs

Andy Chen

Wolfe Research

$47

Buy

19.26%

Upside

Reiterated

04/06/26

Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential

Thomas Smith

Leerink Partners

$52→$50

Buy

26.87%

Upside

Reiterated

04/02/26

Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback

William Pickering

Bernstein

$28

Hold

-28.95%

Downside

Initiated

03/20/26

Immunovant initiated with a Market Perform at BernsteinImmunovant initiated with a Market Perform at Bernstein

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

3 Months

Thomas SmithLeerink Partners

Success Rate

11/19 ratings generated profit

Average Return

+17.37%

Copying Thomas Smith's trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +17.37% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

11/19 ratings generated profit

Average Return

+55.32%

Copying Thomas Smith's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +55.32% per trade.

2 Years

Thomas SmithLeerink Partners

Success Rate

14/19 ratings generated profit

Average Return

+84.28%

Copying Thomas Smith's trades and holding each position for 2 Years would result in 73.68% of your transactions generating a profit, with an average return of +84.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMVT has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is 50.55.

Each month's total comprises the sum of three months' worth of ratings.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.72 with a range of -$0.79 to -$0.53. The previous quarter’s EPS was -$0.75. IMVT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.

No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunovant, Inc.’s 12-month average price target is 50.55.

What is IMVT’s upside potential, based on the analysts’ average price target?

Immunovant, Inc. has 28.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMVT a Buy, Sell or Hold?

Immunovant, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Immunovant, Inc.’s price target?

The average price target for Immunovant, Inc. is 50.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $66.00 ,the lowest forecast is $30.00. The average price target represents 28.26% Increase from the current price of $39.41.

What do analysts say about Immunovant, Inc.?

Immunovant, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of IMVT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immunovant (IMVT) Stock Forecast & Price Target

IMVT Analyst Ratings

IMVT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunovant

IMVT Analyst Recommendation Trends

IMVT Financial Forecast

IMVT Earnings Forecast

IMVT Sales Forecast

IMVT Stock Forecast FAQ

Detailed List of Analyst Forecasts